Functional Brands Reports $9.6M Loss, Defaults on Series C and Notes, Going Concern Doubt
MEHA sits 22% above its 52-week low of $0.004.
Summary
Functional Brands Inc. reported a $9.6 million net loss for H1 2026, disclosed going concern doubt, and is in default on its Series C Preferred and Senior Secured Convertible Notes after missing a mandatory redemption and losing its Nasdaq listing.
Key Events · Earnings and Guidance · MEHA
-
Going Concern Doubt
Cash of $352,142, working capital deficit of $2,903,380, and accumulated deficit of $16,679,712 raise substantial doubt about the company's ability to continue as a going concern.
-
Defaults on Series C and Notes
Failure to commence mandatory redemption on June 8, 2026, and Nasdaq delisting on June 16, 2026, constitute events of default under the Series C Preferred and Senior Secured Convertible Notes.
-
Default Penalties
Dividend rate on Series C increased to 24%, Notes obligations increased to 125%, default interest rate of 24%, monthly monitoring fee of $5,000, and conversion price reduced to 85% of lowest trading price.
-
Massive Net Loss
Net loss of $9,621,337 for the six months ended June 30, 2026, driven by a $6,310,464 loss on preferred stock issuance and a $942,568 change in fair value of derivative liabilities.
Analysis · MEHA · Life Sciences
The 10-Q reveals the company is in default on its Series C Preferred and Senior Secured Convertible Notes due to missed mandatory redemption and Nasdaq delisting. Cash has dwindled to $352,142 against a working capital deficit of $2.9 million, raising substantial doubt about its ability to continue as a going concern. The defaults trigger a 24% dividend rate, a 125% obligation increase on the Notes, and a conversion price cut to 85% of the lowest trading price, which could lead to massive dilution if holders convert. The company also recognized a $6.3 million loss on preferred stock issuance and a $942,568 derivative loss, driving a net loss of $9.6 million for the first half of 2026.
At the time of this filing, MEHA was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $206.8K. The 52-week trading range was $0.00 to $8.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.